Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Teli Hsueh"'
Autor:
Florante Ricarte, Rosa Menjivar, Surya Chhun, Tattika Soreta, Lisa Oliveira, Teli Hsueh, Maribeth Serranilla, Editte Gharakhanian
Publikováno v:
PLoS ONE, Vol 6, Iss 8, p e23696 (2011)
Vacuoles of yeast Saccharomyces cerevisiae are functionally analogous to mammalian lysosomes. Both are cellular organelles responsible for macromolecular degradation, ion/pH homeostasis, and stress survival. We hypothesized that undefined gene functi
Externí odkaz:
https://doaj.org/article/1a26373c8b454fbaad8445c16a829c28
Autor:
Tim F Cloughesy, Koji Yoshimoto, Phioanh Nghiemphu, Kevin Brown, Julie Dang, Shaojun Zhu, Teli Hsueh, Yinan Chen, Wei Wang, David Youngkin, Linda Liau, Neil Martin, Don Becker, Marvin Bergsneider, Albert Lai, Richard Green, Tom Oglesby, Michael Koleto, Jeff Trent, Steve Horvath, Paul S Mischel, Ingo K Mellinghoff, Charles L Sawyers
Publikováno v:
PLoS Medicine, Vol 5, Iss 1, p e8 (2008)
There is much discussion in the cancer drug development community about how to incorporate molecular tools into early-stage clinical trials to assess target modulation, measure anti-tumor activity, and enrich the clinical trial population for patient
Externí odkaz:
https://doaj.org/article/6c668f88ea25476fae7fe61ad50c3162
Autor:
Ikha M. Siddiqah, Stephanie M. Cocca, Teli Hsueh, Vanessa Cervantes, Editte Gharakhanian, Surya P. Manandhar
Lipid droplets (LDs) have emerged as dynamic and interactive organelles with important roles in lipid metabolism and membrane biogenesis. Here, we report that Saccharomyces cerevisiae Env9 is a novel conserved oxidoreductase involved in LD morphology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::414f4b04cc90e89b9f7225c5f4d62271
https://europepmc.org/articles/PMC5802364/
https://europepmc.org/articles/PMC5802364/
Autor:
David Linhart, William R. Sellers, Levi A. Garraway, Gad Getz, Jordi Barretina, Julie H. Huang, Roman K. Thomas, Kinjal Shah, Ralph M. Debiasi, Matthew Meyerson, John R. Prensner, Leia Nghiemphu, Paul S. Mischel, Teli Hsueh, Mark A. Rubin, Francesca Demichelis, Todd Golub, Eric S. Lander, Ingo K. Mellinghoff, Jeffrey C. Lee, Stan F. Nelson, Sven Perner, Charlie Hatton, Rameen Beroukhim, Tweeny R Kau, Igor Vivanco, Sethu Alexander, Linda M. Liau, Jinyan Du, Horacio Soto, Timothy F. Cloughesy
Publikováno v:
Proceedings of the National Academy of Sciences. 104:20007-20012
Comprehensive knowledge of the genomic alterations that underlie cancer is a critical foundation for diagnostics, prognostics, and targeted therapeutics. Systematic efforts to analyze cancer genomes are underway, but the analysis is hampered by the l
Autor:
Narsis Attar, Jonathan E. Zuckerman, Qi Wang, Richard C. Koya, Erika von Euw, Teli Hsueh, Ramin Nazarian, Antoni Ribas, Jonas Nørskov Søndergaard, Laura E. MacConaill, Bartosz Chmielowski, Hooman Sazegar, Paul S. Mischel, Stephen Mok, Begoña Comin-Anduix, Jordi Barretina, Deliang Guo, Roger S. Lo, Sarah M. Kehoe
Publikováno v:
Journal of Translational Medicine, Vol 8, Iss 1, p 39 (2010)
Søndergaard, Jonas N; Nazarian, Ramin; Wang, Qi; Guo, Deliang; Hsueh, Teli; Mok, Stephen; et al.(2010). Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific raf inhibitor PLX4032. Journal of Translational Medicine, 8(1), 39. doi: http://dx.doi.org/10.1186/1479-5876-8-39. Retrieved from: http://www.escholarship.org/uc/item/04v2t4wb
Journal of Translational Medicine
Søndergaard, J N, Nazarian, R, Wang, Q, Guo, D, Hsueh, T, Mok, S, Sazegar, H, Macconail, L E, Barretina, J G, Kehoe, S M, Attar, N, von Euw, E, Zuckerman, J E, Chmielowski, B, Comin-Anduix, B, Koya, R C, Mischel, P S, Lo, R S & Ribas, A J 2010, ' Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific raf inhibitor PLX4032 ', Journal of Translational Medicine, vol. 8 . https://doi.org/10.1186/1479-5876-8-39
Søndergaard, Jonas N; Nazarian, Ramin; Wang, Qi; Guo, Deliang; Hsueh, Teli; Mok, Stephen; et al.(2010). Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific raf inhibitor PLX4032. Journal of Translational Medicine, 8(1), 39. doi: http://dx.doi.org/10.1186/1479-5876-8-39. Retrieved from: http://www.escholarship.org/uc/item/04v2t4wb
Journal of Translational Medicine
Søndergaard, J N, Nazarian, R, Wang, Q, Guo, D, Hsueh, T, Mok, S, Sazegar, H, Macconail, L E, Barretina, J G, Kehoe, S M, Attar, N, von Euw, E, Zuckerman, J E, Chmielowski, B, Comin-Anduix, B, Koya, R C, Mischel, P S, Lo, R S & Ribas, A J 2010, ' Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific raf inhibitor PLX4032 ', Journal of Translational Medicine, vol. 8 . https://doi.org/10.1186/1479-5876-8-39
Blocking oncogenic signaling induced by the BRAF V600E mutation is a promising approach for melanoma treatment. We tested the anti-tumor effects of a specific inhibitor of Raf protein kinases, PLX4032/RG7204, in melanoma cell lines. PLX4032 decreased
Autor:
Teli Hsueh, Tom Oglesby, Koji Yoshimoto, Charles L. Sawyers, Michael Koleto, Paul S. Mischel, Don Becker, Marvin Bergsneider, Steve Horvath, Yinan Chen, Jeff Trent, David Youngkin, Neil A. Martin, Julie Dang, Shaojun Zhu, Wei-wei Wang, Linda M. Liau, Timothy F. Cloughesy, Kevin M. Brown, Albert Lai, Richard M. Green, Phioanh L. Nghiemphu, Ingo K. Mellinghoff
Publikováno v:
PLoS Medicine, Vol 5, Iss 1, p e8 (2008)
PLoS Medicine
PLoS Medicine
There is much discussion in the cancer drug development community about how to incorporate molecular tools into early-stage clinical trials to assess target modulation, measure anti-tumor activity, and enrich the clinical trial population for patient
Autor:
Cloughesy, Tim F., Yoshimoto, Koji, Phioanh Nghiemphu, Brown, Kevin, Dang, Julie, Shaojun Zhu, Teli Hsueh, Yinan Chen, Wei Wang, Youngkin, David, Liau, Linda, Martin, Neil, Becker, Don, Bergsneider, Marvin, Lai, Albert, Green, Richard, Oglesby, Tom, Koleto, Michael, Trent, Jeff, Horvath, Steve
Publikováno v:
PLoS Medicine; Jan2008, Vol. 5 Issue 1, pe8, 13p, 1 Diagram, 2 Charts, 3 Graphs
Publikováno v:
Journal of Investigative Dermatology. (2):453-460
Systemically delivered small interfering RNA (siRNA) therapies for cancer have begun clinical development. The effects of siRNA-mediated knockdown of ribonucleotide reductase subunit-2 (RRM2), a rate-limiting enzyme in cell replication, were investig